![Brian Burkavage](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 35 $ in data 31/05/2026
Brian Burkavage is Chief Financial & Accounting Officer at Damora Therapeutics, Inc. starting in 2026.
Former positions include Chief Accounting Officer at IO Biotech, Inc. from 2022 to 2025, Controller at Passage Bio, Inc. from 2020 to 2021, and Director-Financial Planning & Analysis at Aclaris Therapeutics, Inc. from 2017 to 2020.
Education includes undergraduate and graduate degrees from the University of Notre Dame.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
IO BIOTECH, INC. 0,02% | 02/04/2025 | 11.500 ( 0,02% ) | 35 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| DAMORA THERAPEUTICS, INC. | Direttore Finanziario/CFO | 01/05/2026 |
| Società | Posizione | Fine |
|---|---|---|
| IO BIOTECH, INC. | Comptroller/Controller/Auditor | 12/12/2025 |
| PASSAGE BIO, INC. | Comptroller/Controller/Auditor | 01/01/2021 |
| ACLARIS THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2020 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
University of Notre Dame
 University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aclaris Therapeutics, Inc.
 Aclaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel drug candidates for immuno-inflammatory diseases | Health Technology |
Passage Bio, Inc.
 Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
Galecto, Inc.
 Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases | Health Technology |
IO Biotech, Inc.
 IO Biotech, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel, immune-modulating cancer therapies | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
